Journal
ZEITSCHRIFT FUR GASTROENTEROLOGIE
Volume 50, Issue 9, Pages 1018-1027Publisher
GEORG THIEME VERLAG KG
DOI: 10.1055/s-0032-1312771
Keywords
hepatocellular carcinoma; sorafenib; targeted therapy
Categories
Funding
- Bayer Healthcare
Ask authors/readers for more resources
Sorafenib, a receptor tyrosine kinase-inhibitor with anti-proliferative and anti-angiogenic activity, is currently the only approved systemic treatment for patients with hepatocellular carcinoma. It inhibits downstream signaling of VEGFR-2, PDGFR, c-Kit receptors and BRAF. Over the last four years comprehensive experience with sorafenib in this indication has been accumulated. In this review we discuss the current data on the use of sorafenib in patients with advanced HCC including special patient populations such as patients with impaired liver function, patients after transplantation, and others. The most frequent side-effects and practical tips on how to manage them are discussed in detail. In addition, we summarize the current experimental data on the use of sorafenib in combination treatment, e.g., together with transarterial chemoembolisation or other targeted agents.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available